Eli Lilly Q1 sales blowout lifts 2026 guide

Key Takeaways

• Q1 2026 revenue: $19.8 billion (+56% vs Q1 2025).
• Mounjaro worldwide: $8.7 billion (+125%); U.S. $4.2 billion (+59%).
• Zepbound worldwide: $4.2 billion (+80%) in the same quarter.
• 2026 revenue guide raised to $82–$85 billion; non-GAAP EPS to $35.50–$37.00.

How big was the Eli Lilly Q1 sales blowout?

Lilly reported Q1 2026 worldwide revenue of $19.8 billion, up 56% from Q1 2025. Growth came from a 65% volume increase, partly offset by a 13% hit from lower realized prices, including Mounjaro and Zepbound price dynamics.

Primary filing exhibit: SEC Q1 2026 sales and earnings release.

What did Mounjaro and Zepbound contribute?

Worldwide Mounjaro revenue rose 125% to $8.7 billion. U.S. Mounjaro was $4.2 billion (+59%), with strong demand partly offset by lower realized prices and a favorable one-time rebate/discount estimate adjustment. Ex-U.S. Mounjaro reached $4.4 billion versus $1.2 billion a year earlier, helped by China NRDL volume.

Zepbound worldwide revenue was about $4.2 billion (+80%). Together, the tirzepatide brands dominate the cardiometabolic growth story in the SEC tables.

How did full-year 2026 guidance change?

Lilly lifted full-year 2026 revenue guidance by $2 billion on each end, to $82.0–$85.0 billion from $80–$83 billion. Non-GAAP EPS guidance rose to $35.50–$37.00 from $33.50–$35.00. Performance-margin guidance also moved higher, to 47.0%–48.5%.

• Prior revenue guide: $80–$83 billion
• Updated revenue guide: $82–$85 billion
• Q1 reported EPS: $8.26 (+170%)
• Q1 non-GAAP EPS: $8.55 (+156%)

Price versus volume: what investors should separate

Management framed the quarter as volume-led with low-to-mid-teens full-year price headwinds still expected. That split matters for models: unit demand can stay strong while realized net price declines in the U.S. and in markets such as China after NRDL listing.

Segment detail is also in Lilly’s Q1 2026 Form 10-Q XBRL tables on SEC R7 revenue breakouts.

Why volume growth still carries price risk

The Eli Lilly Q1 sales blowout was not price-led. Volume rose 65% while realized prices reduced revenue by about 13%. Management still expects low-to-mid-teens price headwinds for the full year, even after lifting the revenue guide by $2 billion.

That combination—strong unit demand plus net-price pressure—is typical for incretin franchises once access widens. China NRDL listing boosted ex-U.S. Mounjaro volume to $4.4 billion, but also intensified price dynamics that models must not ignore when extrapolating Q1 run-rates.

How guidance mechanics matter for consensus

Moving the 2026 revenue band from $80–$83 billion to $82–$85 billion is a clean $2 billion parallel shift. Non-GAAP EPS moved by $2.00 at both ends to $35.50–$37.00. Performance margin guidance also rose to 47.0%–48.5%, reflecting higher operating profit on higher sales.

SEC exhibit language attributes Q1 strength primarily to Mounjaro and Zepbound volume. Key Products revenue reached $13.4 billion. Those SEC figures, not sell-side adjectives alone, are the diligence baseline for any “blowout” narrative this quarter.

What remains unproven from one quarter

A single quarter’s Eli Lilly Q1 sales blowout does not lock full-year delivery at the high end of guidance. Competitive incretin launches, manufacturing constraints, and further net-price pressure can still reset the path. Pipeline comments in the same release should be tracked separately from Mounjaro cash flows.

Related NovaPharma coverage

• Eli Lilly company profile
• Tirzepatide (Mounjaro/Zepbound)
• CagriSema Phase 3 obesity catalyst

Frequently Asked Questions

Primary Sources

1. SEC: Lilly Q1 2026 sales and earnings press exhibit
2. SEC: Q1 2026 revenue product breakout (R7)
3. SEC: Lilly Form 10-Q for quarter ended March 31, 2026